Celyad Oncology Long Term Debt

As of the most recent data (June 2024), CYAD shows a long-term debt of $830K. That compares with $340K in the prior-year period — up 146.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYAD's long-term debt is now $830K (was $340K) — a 146.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Celyad Oncology is outperforming or lagging.

Tracking CYAD's long-term debt over time shows whether Celyad Oncology is scaling, shrinking, or reshaping that part of the business. The current reading is $830K That compares with $340K in the prior-year period — up 146.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Celyad Oncology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $830K) with ownership activity and broader fundamentals.

Celyad Oncology's long-term debt is $830K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.